Business, energy, technology, markets and global industry news from Business News Today

CRENESSITY

PharmaDeviceNews CRENESSITY
Pharma & Biotech

Can Vertex turn its $10bn Crinetics deal into a rare endocrinology powerhouse?

Discover why Vertex is paying $10 billion for Crinetics and how Palsonify and atumelnant could reshape rare endocrine treatment.

Read More
Representative image of an endocrinology researcher reviewing adrenal hormone data, as Neurocrine Biosciences’ Crenessity update at ENDO 2026 raises new questions about treatment options for classic congenital adrenal hyperplasia.
Pharma & Biotech

Could Crenessity move beyond 21-hydroxylase CAH after Neurocrine’s ENDO 2026 data?

Find out how Neurocrine’s Crenessity data could expand rare CAH treatment thinking while key clinical questions remain.

Read More
Crenessity two-year data highlight growing interest in long-term congenital adrenal hyperplasia treatment, steroid reduction, and endocrine outcomes. Representative image.
Pharma & Biotech

Neurocrine builds long-term case for Crenessity in congenital adrenal hyperplasia

See how Neurocrine’s two-year Crenessity data may reshape long-term classic CAH care, steroid reduction and pediatric outcomes.

Read More
Representative image: Pediatric endocrine care is drawing renewed attention as Neurocrine Biosciences’ CRENESSITY two-year CAHtalyst Pediatric data show durable hormone control, reduced glucocorticoid exposure and potential long-term clinical benefits for children with classic congenital adrenal hyperplasia.
Pharma & Biotech

Neurocrine’s CAHtalyst pediatric data sharpens the case for CRENESSITY durability

Steroid reduction is the real test in pediatric CAH. Neurocrine’s CRENESSITY data now faces the durability, access and adoption question.

Read More